376 related articles for article (PubMed ID: 15156345)
1. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors.
Warren KE; Patel MC; Aikin AA; Widemann B; Libucha M; Adamson PC; Neuwirth R; Benziger D; O'Toole T; Ford K; Patronas N; Packer RJ; Balis FM
Cancer Chemother Pharmacol; 2001 Oct; 48(4):275-82. PubMed ID: 11710627
[TBL] [Abstract][Full Text] [Related]
3. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
Warren K; Jakacki R; Widemann B; Aikin A; Libucha M; Packer R; Vezina G; Reaman G; Shaw D; Krailo M; Osborne C; Cehelsky J; Caldwell D; Stanwood J; Steinberg SM; Balis FM
Cancer Chemother Pharmacol; 2006 Sep; 58(3):343-7. PubMed ID: 16408203
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours.
Thomas HD; Lind MJ; Ford J; Bleehen N; Calvert AH; Boddy AV
Cancer Chemother Pharmacol; 2000; 45(4):284-90. PubMed ID: 10755316
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin pharmacokinetics in young children with brain tumors.
Tonda ME; Heideman RL; Petros WP; Friedman HS; Murry DJ; Rodman JH
Cancer Chemother Pharmacol; 1996; 38(5):395-400. PubMed ID: 8765431
[TBL] [Abstract][Full Text] [Related]
7. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters.
Emerich DF; Snodgrass P; Dean R; Agostino M; Hasler B; Pink M; Xiong H; Kim BS; Bartus RT
Br J Cancer; 1999 Jun; 80(7):964-70. PubMed ID: 10362103
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.
Obasaju CK; Johnson SW; Rogatko A; Kilpatrick D; Brennan JM; Hamilton TC; Ozols RF; O'Dwyer PJ; Gallo JM
Clin Cancer Res; 1996 Mar; 2(3):549-52. PubMed ID: 9816202
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
10. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
11. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
12. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival.
Bartus RT; Snodgrass P; Marsh J; Agostino M; Perkins A; Emerich DF
J Pharmacol Exp Ther; 2000 Jun; 293(3):903-11. PubMed ID: 10869391
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
[TBL] [Abstract][Full Text] [Related]
14. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
15. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum iohexol clearance for use in predicting carboplatin clearance in cats.
Bailey DB; Rassnick KM; Prey JD; Dykes NL
Am J Vet Res; 2009 Sep; 70(9):1135-40. PubMed ID: 19719430
[TBL] [Abstract][Full Text] [Related]
17. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.
Plummer R; Woll P; Fyfe D; Boddy AV; Griffin M; Hewitt P; Carmichael J; Namouni F; Cohen M; Verrill M
Clin Cancer Res; 2008 Dec; 14(24):8288-94. PubMed ID: 19088046
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
20. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
Neuwelt EA; Gilmer-Knight K; Lacy C; Nicholson HS; Kraemer DF; Doolittle ND; Hornig GW; Muldoon LL
Pediatr Blood Cancer; 2006 Aug; 47(2):174-82. PubMed ID: 16086410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
